



## FOR IMMEDIATE RELEASE

Contact:  
Misha Plam  
President & CEO  
AmideBio, LLC  
[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)  
(303) 641-3669  
<http://www.AmideBio.com>

### **Dr. Michael Stowell, CTO of AmideBio, to Speak in Strategy Discussion Forum at TIDES Conference on May 22, 2012**

**Boulder, CO February 17, 2012** -- AmideBio, LLC, which is focused on a novel recombinant process to improve the production and commercialization of technically-challenging peptides for the R&D, clinical and therapeutic marketplaces today announced that Dr. Michael Stowell, Founder and Chief Technology Officer, will be a featured panelist at the TIDES “Oligonucleotide and Peptide” Conference May 20-23, 2012 in Las Vegas, NV. Dr. Stowell will be a panelist in the conference’s Strategy Discussion Forum “When to Choose Recombinant vs. Synthetic Production of Peptides: The Complexities of a ‘Simple’ Decision”, Tuesday, May 22, 2012 at 11:25 AM.

More information about the conference is available at: [www.IBCLifeSciences.com/TIDES](http://www.IBCLifeSciences.com/TIDES)

#### **About AmideBio, LLC**

AmideBio, is a biotechnology company focused on providing peptide research and clinical products for a diverse array of research and commercial targets. AmideBio addresses the challenges of historically difficult to manufacture peptides by using its proprietary technology to minimize toxicity during bacterial growth and in the chemical synthesis waste-stream, thereby simplifying downstream processing and reducing overall costs of development and manufacturing. AmideBio emphasizes the application of economically sensitive and environmentally sustainable practices. For more information please visit <http://www.AmideBio.com>